ClinicalTrials.gg
RecruitingNCT07415655MOZEGUpdated May 6, 2026

Modulation of Cerebral Ischemia by Albumin

A Phase 2 interventional study of Albumin infusion and Placebo Injection in Ischemic Stroke, sponsored by University Hospital Hradec Kralove. Recruiting at 1 site in Czechia. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-05-06.

Sponsored by University Hospital Hradec Kralove · Phase 2, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Feb 2026; still recruiting 9 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
100
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 29 studies in Ischemic Stroke with a site in Czechia — 8 open to participants now, 10 under way, 1 of them phase 3. Ischemic Stroke · Czechia.

Planned enrollment
18th of 21
100 · median 532
Started
2026
the only one that year
Phase 2
7 of 29
1 open now
Registered
29th of 29
by date

Among the 29 studies in Ischemic Stroke with a site in Czechia, this one is the 18th largest by planned enrollment of the 21 interventional ones that give a count, is the only one that started in 2026, is one of 7 in phase 2, and was the 29th registered.

Ischemic Stroke

2,629 studies on the registry are indexed under Ischemic Stroke; 983 are open to participants now.

Browse Ischemic Stroke studies →

Open to participants now

8 of the 29 studies in Ischemic Stroke with a site in Czechia are open now. Recruiting first, the newest first:

2 more — sign in →

All 8 open studies →

A study can be open while its sites in Czechia have not opened yet or have stopped. Only those recruiting at a site in Czechia →

Who these studies take

Of the 668 Ischemic Stroke studies recruiting now, 403 (60%) set no upper age limit and 62 (9%) stop at 75 or younger; 27 take children under 18; 41 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 29 studies in Ischemic Stroke with a site in Czechia, or all of them as a file.
02

Study summary

A single-center, open-label, randomized, placebo-controlled, prospective phase II clinical trial to investigate the efficacy of low-dose albumin in patients with ischemic stroke with an indication for vasographic intervention. The clinical trial consists of the following phases: Screening, randomization, treatment phase - administration of albumin/placebo and vasographic intervention (with the duration of all these 3 phases in the order of hours) and a follow-up phase, which takes place first in the intensive care unit (ICU) and then in a standard ward and lasts 90 (±7) days. The clinical trial ends with the End of Study/Day 90 visit. The total maximum duration of patient participation in the clinical trial is therefore 97 days, including Follow-up.

Ischemic stroke is caused by local perfusion impairment due to thromboembolism or thrombosis at the site of perfusion impairment. The damaged brain area is projected into the patient's neurological clinical picture. The primary stroke cannot be influenced by therapeutic procedures, however, the area of the so-called penumbra (the surroundings of the ischemic lesion, where vasoreactivity is impaired and the blood-brain barrier is more or less damaged) can be, which is the main goal of therapy, as well as improving the neurological clinical outcome of patients as much as possible (thrombolysis, neuroangiointervention). Research over the past 20 years has highlighted the importance of the endothelial glycocalyx (EG) and has proposed a number of concepts and substances with a protective and reparative effect.

Albumin has come to the forefront of interest. The study assumes a benefit for patients in the form of non-circulatory effects of administered albumin: improvement of EG condition in the penumbra area of the ischemic focus, improvement of microrheology, and antioxidant protection. Albumin therapy has been used for 80 years and is generally well tolerated. Allergy to albumin is rare, as it is a protein of the body's own from healthy donors. The concomitantly used medicinal products are highly purified. The selected dosage should not endanger the patient in any way in terms of circulatory overload, pulmonary edema, and, we assume, also in terms of bleeding into the ischemic focus of the brain.

Study drug: albumin. Any albumin available on the market in the dose and strength specified in the protocol can be used. The reference SmPC is Alburex (manufacturer CSL Behring). Placebo: Fresenius Kabi 0.9% saline solution.

It is planned to enroll 100 patients.

03

Conditions studied

  • Ischemic Stroke

Browse trials for

Keywords

  • endothelial glycocalyx
  • ischemic stroke
  • albumin
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • ischemic stroke in the anterior circulation with or without thrombolysis administration
  • vasographic intervention indication

Exclusion criteria

Exclusion Criteria:

  • pregnancy, breastfeeding
  • known albumin
  • hypervolemia, hyperhydration
  • hypernatremia
  • another study participation
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
100 participants (estimated)

Study arms

  • Experimental
    Albumin group

    Drug: Albumin infusion

  • Placebo comparator
    Placebo

    Drug: Placebo Injection

Interventions

  • DrugAlbuminsStudies of AlbuminsAlbumins pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Albumin will be given to the eligible patients during the vasographic intervention intravenously within 20 minutes. The dose is unified for all participants - 100 ml of 20 % human serum albumin.

    Also known as: Albumin

  • DrugPlacebo Injection

    Normal saline as a placebo will be given to the eligible patients during the vasographic intervention intravenously within 20 minutes. The dose is unified for all participants: 100 ml of 0,9 % sodium chloride.

    Also known as: Normal saline

06

What researchers measure

Primary outcomes

  1. Syndecan-1 serum concentration

    Assessment of syndecan-1 in the serum by the ELISA method. Results are a concentration in ng/ml.

    Time frame: Baseline, in 12 hours, 24 hours, 48 hours and 72 hours.

  2. Glycoyaminoglycans in the urine concentration

    The concentration of all the glycosaminoglycans excreted into the urine. The assessment by spectrophotometry. Concentration in mg/ml.

    Time frame: Baseline, in 12 hours, 24 hours, 48 hours and 72 hours.

Secondary outcomes

  1. The brain ischemia volume

    Assessment of the ischemia of the brain after a vasographic intervention on the follow-up CT scan calculated using a three-dimensional equation.

    Time frame: In 12 to 24 hours.

  2. Neurological outcome

    Neurological outcome assessed by the modified Rankin scale (7-level scale.

    Time frame: 90 days.

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Feb 2026 (actual). Primary completion is estimated for Feb 2027, 11 months after the start.

Of 82 non-industry phase 2 interventional studies under Ischemic Stroke, half reached primary completion within 29 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 40. This study's planned 11 months is below that.

Counting every sponsor, half of 123 studies reached it within 28 months; a quarter within 15 and three quarters within 39.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 29, 2026
First posted
Feb 17, 2026
StartActual
Feb 3, 2026
Primary completionEst.
Feb 1, 2027
CompletionEst.
Feb 1, 2028
Last update
May 6, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 6, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07415655
Lead sponsor
University Hospital Hradec Kralove
Responsible party
Sponsor
First posted
Feb 17, 2026
Start date
Feb 3, 2026
Primary completion
Feb 1, 2027 (estimated)
Completion
Feb 1, 2028 (estimated)
Last update
May 6, 2026

Study contacts

David Astapenko, M.D., Ph.D., MBA
Contact
david.astapenko@fnhk.cz
+420495833218

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Albumins

Start the discussion